Morepen to launch new fatty lever drug ‘Resmetirom’

Merck to acquire US Biopharma firm SpringWorks Therapeutics for enterprise value of $3.4 billion

Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide

Remedium unveils Rights Issue post Rs. 182.7 crore UK deal to drive global expansion

The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience

Carbogen Amcis Shanghai site receives drug manufacturing license from Chinese NMPA

Paras Healthcare introduces radiation oncology facility at Ranchi

The newly inaugurated facility bridges this gap by offering metro-grade treatment closer to home

AstraZeneca, Daiichi Sankyo announce Enhertu plus pertuzumab demonstrated clinically meaningful improvement as 1st-line therapy for patients with metastatic breast cancer

DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care

MoS Health Jadhav inaugurates FSSAI’s stakeholder consultation on sustainable packaging

Over 1500 stakeholders representing food businesses, packaging industries, recycling associations, regulatory bodies, environmental organizations, consumer groups, farmer groups, government departments participated in the consultation

GSK’s blenrep combinations approved by UK MHRA in relapsed/refractory multiple myeloma

Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed

CCI approves merger between Aster DM Healthcare and Quality Care India

The merged entity ‘Aster DM Quality Care’ will be jointly controlled by Aster Promoters and Blackstone

Rockwell Automation empowers NKP Pharma achieve regulatory compliance

By integrating Rockwell Automation’s FactoryTalk Optix, NKP Pharma has achieved compliance with USFDA 21 CFR Part 11